GlassScriptPhysician profile
Eliazar Alvarez
NPI 1215997259
$4,466.02
in general payments reported to CMS, 2019-2025
30 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $112 · 2021: $125 · 2022: $421 · 2023: $809 · 2024: $672 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $560.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $554.40 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $502.82 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $342.40 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $255.13 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.35 | 2019-2025 | Jardiance |
| Tris Pharma INC | $231.40 | 2019-2022 | |
| Pfizer INC. | $223.71 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $212.33 | 2021-2025 | Qelbree |
| Abbott Laboratories | $199.15 | 2022-2025 | Freestyle Libre 3, Jot Dx, Proclaim |
| Exact Sciences Corporation | $164.25 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $155.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.94 | 2019 | |
| Astellas Pharma US INC | $102.34 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $101.46 | 2024-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $96.54 | 2025 | Korlym |
| Boston Scientific Corporation | $72.96 | 2019-2020 | |
| Amgen INC. | $64.40 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $43.47 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $37.01 | 2019-2022 | |
| Recor Medical INC | $25.29 | 2025 | Paradise Ultrasound Renal Denervation System |
| Philips North America LLC | $22.27 | 2024 | (Ck7) Extended Holter |
| Shield Therapeutics INC | $21.97 | 2025 | |
| Melinta Therapeutics, LLC | $20.30 | 2019 | |
| Dexcom, INC. | $20.22 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $19.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.70 | 2022 | |
| Abbvie INC. | $14.55 | 2023 | Qulipta |
| Sanofi Pasteur INC. | $11.82 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliazar Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.